MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'avodart'. Sat, 03 Sep 2011 02:39:30 +0100 http://www.medworm.com/index.php?rid=4627023&cid=t_167210_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FQC6EHv3GSyQ%2F Good morning, everyone. A spot of snow is falling on the Pharmalot corporate campus today. So much for spring. Nonetheless, we persevere thanks, in part, to a cup of stimulation - our flavor today is Southern Pecan. Meanwhile, we are gearing up for those meetings and deadlines, and trust you are doing the same. To help you along, here are some tidbits from around the world. Hope you have a productive day and catch you soon… Novartis Must Wait Longer For FDA Decision On COPD Drug (Reuters) Glaxo Scraps Plan To Market Prostate Cancer Med (Associated Press) Former Pfizer CEO And His Severance (Associated Press) Medicare Ordered To Pay For Off-Label Drugs (American Medical News) Bristol Pays CEO Andreotti $11M In Compensation (Associated Press) Gilead HIV Drug Meets Main Trial Goal (Reut... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4627023 Wed, 23 Mar 2011 12:05:07 +0100 4627023 http://www.medworm.com/index.php?rid=4220458&cid=t_167210_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F7L5bE1wLCDc%2F Maybe GlaxoSmithKline sales reps deserve a bonus. A new survey of more than 1,800 primary care physicians ranked the drugmaker’s field force as the best, even as sales calls to these docs - which include general practitioners, family med physicians and doctors of osteopathy - fell 12 percent in the 12 months ending September 2010, compared with the previous 12-month period. On a score of 1 to 7, Glaxo’s average quality score was 5.71, up from 5.54 in 2009, according to SDI Health, a market research firm that conducted the survey. The showing catapulted Glaxo from third place last year, when the drugmaker followed Pfizer and Merck, both of which moved down a notch from the No. 1 and No. 2 slots, respectively. On a related note, in both years, 97 percent of the docs indicated they w... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4220458 Wed, 01 Dec 2010 13:01:57 +0100 4220458 http://www.medworm.com/index.php?rid=3943022&cid=t_167210_150_f&fid=34889&url=http%3A%2F%2Fpharmamkting.blogspot.com%2F2010%2F09%2Fwill-avandia-failure-lead-to-more.html In a BMJ editorial, editor Fiona Godlee contends that Avandia "should not have been licensed and should now be withdrawn." She cites problems that FDA discovered with the RECORD post-marketing study and finds fault with regulatory agencies' oversight of such studies.Regulators should "should require a higher quality of evidence," Godlee says, "including proof that new drugs are better than existing drugs before being licensed. And if they do ask the manufacturer to undertake post-marketing trials, they must do a better job of overseeing the way these trials are designed and done."Godlee also called for other reforms, including "far greater transparency from industry and the regulators, including access to raw data and funding for independent trials..."Holding out a carrot in front of this ... Pharma Marketing Blog blogs http://www.medworm.com/rss/comments.php?id=3943022 Tue, 07 Sep 2010 14:00:00 +0100 3943022 http://www.medworm.com/index.php?rid=3795058&cid=t_167210_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FD0NH6tKr4gk%2F File this under ’should have known better.’ Last year, GlaxoSmithKline wanted to promote its Avodart drug for shrinking enlarged prostates, so it paid for a supplement in the May 2009 edition of Urology. But the articles contained info about studies suggesting Avodart could reduce the risk of developing prostate cancer - and the FDA never approved Avodart for that use. One article claimed Avodart may be more effective than a rival Merck drug, despite a lack of head-to-head studies. And so, two months later, Deirdre Connelly, who heads Glaxo’s North American pharma unit, wrote to apologize to the docs who received Urology. In her letter, Connelly acknowledged Glaxo failed to disclose it helped develop the supplement and select the docs listed as authors. The supplement dis... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3795058 Tue, 27 Jul 2010 11:45:17 +0100 3795058 http://www.medworm.com/index.php?rid=3662930&cid=t_167210_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FlG3_0WmNlLQ%2F Rise and shine. Another day is on the way. To top it off, the sun is shining here on the Pharmalot corporate campus, where we are hustling the short people off to the schoolhouse. Wish us luck. Meanwhile, there is much to do. So why not start with the mandatory cup of stimulation and the news of the world. Have a great day, everyone… Glaxo Wins FDA OK For Prostate Combo Drug (Reuters) Cheap Generic May Save Lives After Bleeding From Accidents (Bloomberg News) ACRO Wants More US & European Trial Investigators (Outsourcing Pharma) Waiting For The Human Genome To Yield Drugs (The New York Times) Georgia Creates Bioscience Center (Atlanta Journal-Constitution) Cleveland Clinics Inks Research Deal With Lipitor Creator (Crain’s Cleveland Business) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3662930 Tue, 15 Jun 2010 11:54:48 +0100 3662930 http://www.medworm.com/index.php?rid=3023414&cid=t_167210_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fcuc_inec6oM%2F Hello, again. Gray skies are hovering over the Pharmalot corporate campus this morning and are expected to remain here awhile. Just the same, our outlook is sunny. And why not? This is a short week. So here are a few items to help you keep your own spirits high. Have a nice day, everyone… BioCryst Blames Conspiracy For Stock Decline (TheStreet.com) Pfizer Waffles On La Jolla Incubator (San Diego Business Journal) Glaxo Blames Admin Error For Yanking Avodart sNDA (PharmaTimes) Glaxo Holds Some Swine-Flu Shots In Canada (Bloomberg News) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3023414 Tue, 24 Nov 2009 13:24:03 +0100 3023414 http://www.medworm.com/index.php?rid=2725002&cid=t_167210_117_f&fid=38856&url=http%3A%2F%2Fwww.timemastermd.com%2F%3Fp%3D694 “Obama-bonics?”  Today, I heard something I never thought would be proclaimed by the President of the United States of America, the leader of the free world, the most powerful man on the planet…he said, “people in America are getting awl wee-weed up.”  Now, I have used a bit of slang in my day, and I’ll admit I am not down with street lingo, but wee weed up?  Is that a form of ebonics mixed with politics?   Or maybe he was thinking of the good old days when he wet his diaper back in Kenya, and began his political career where he  hoped for a “change”?   The only thing for sure is that his poll numbers are going into the toilet these days, and for good reason. Say it ain’t so Joe,” no flow!” Speaking of going into t... Timemaster MD blogs http://www.medworm.com/rss/comments.php?id=2725002 Sat, 22 Aug 2009 04:15:49 +0100 2725002 http://www.medworm.com/index.php?rid=2227210&cid=t_167210_150_f&fid=34889&url=http%3A%2F%2Fpharmamkting.blogspot.com%2F2009%2F03%2Ftooting-my-own-horn-i-beat-apusa-today.html (Source: Pharma Marketing Blog) Pharma Marketing Blog blogs http://www.medworm.com/rss/comments.php?id=2227210 Mon, 02 Mar 2009 18:51:00 +0100 2227210 http://www.medworm.com/index.php?rid=2216608&cid=t_167210_150_f&fid=34889&url=http%3A%2F%2Fpharmamkting.blogspot.com%2F2009%2F02%2Favodart-print-ad-that-fda-missed.html (Source: Pharma Marketing Blog) Pharma Marketing Blog blogs http://www.medworm.com/rss/comments.php?id=2216608 Thu, 26 Feb 2009 15:08:00 +0100 2216608 http://www.medworm.com/index.php?rid=2216611&cid=t_167210_150_f&fid=34889&url=http%3A%2F%2Fpharmamkting.blogspot.com%2F2009%2F02%2Ffda-warns-gsk-about-enlarged-advodart.html (Source: Pharma Marketing Blog) Pharma Marketing Blog blogs http://www.medworm.com/rss/comments.php?id=2216611 Wed, 25 Feb 2009 13:19:00 +0100 2216611 http://www.medworm.com/index.php?rid=1543346&cid=t_167210_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F319036633%2Favodart_fda_approved_for_symptomatic_enlarged_prostate.html The U.S. Food and Drug Administration has approved GlaxoSmithKline(NYSE:GSK) Avodart in combination with tamsulosin for the treatment of symptomatic enlarged prostate.Enlarged prostate is a disease that affects 50% of men over the age of 50 and 90% of men over the age of 80. The disease causes changes in urinary habits and over time the prostate can continue to enlarge and the bladder can loses its ability to empty itself. (Source: PharmaGazette) PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=1543346 Tue, 24 Jun 2008 15:00:19 +0100 1543346 http://www.medworm.com/index.php?rid=1188603&cid=t_167210_150_f&fid=34889&url=http%3A%2F%2Fpharmamkting.blogspot.com%2F2008%2F01%2Fcaucuses-coffee-shop-focus-groups-and.html Discussion of CholesterolBack to politics, where everything is tested in focus groups, even if just gabbing with a few people in a coffee shop.Not only is politics the topic of discussion in coffee shops around America these days, but so is high cholesterol and drugs that treat it. If a cholesterol drug were running in the Rx drug primaries, it would be the Giuliani of candidates! Vytorin and Zetia have dropped out of the race (see "Vytorin and Zetia Are Dead in the Water") and Crestor has re-emerged, phoenix-like, as a contender (see "Crestor Print Ad Touts Plaque Buildup Advantage").In this month's Pharma Marketing News, I published the following article by Jim Avery, professor of advertising at the University of Oklahoma. He recounts his conversation with college-educated friends at a l... Pharma Marketing Blog blogs http://www.medworm.com/rss/comments.php?id=1188603 Wed, 30 Jan 2008 11:51:00 +0100 1188603